From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

BIOSPAIN showed how partnering conferences connect public funding, venture capital, and pharma to drive biotech innovation to ...

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so ...

The Asabys-Aliath integration signals how European biotech VCs are scaling and adapting amid funding pressures.

The Nordic Life Science (NLS) Days took place this week, October 13–14, in Gothenburg, Sweden. Labiotech was on site to take the pulse of the Nordic biotech scene, and, more specifically, of Sweden’s ...

Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals ...

Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS).

Today, Europe stands as a critical region for biotech companies looking to advance medical breakthroughs in specialized fields, including oncology, rare diseases, and cell and gene therapy. In ...